Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-06-01

Summary

To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.

• Phase: PHASE2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Rigel Pharmaceuticals
• Treatments: Cladribine; Cytarabine; gilteritinib; olutasidenib; ruxolitinib; venetoclax